Scinai Immunotherapeutics FY Results Show Cash Runway Pressure Scinai reported FY results on Apr 2, 2026: net loss $7.6m, cash $4.2m at Dec 31, 2025, implying roughly a 6–7 month runway at current burn (company filing/Seeking Alpha).

Scinai Immunotherapeutics FY Results Show Cash Runway Pressure: Scinai reported FY results on Apr 2, 2026: net loss $7.6m, cash $4.2m at Dec 31, 2025, implying roughly a 6–7 month runway at current… 👈 Read full analysis #ScinaiImmunotherapeutics #FinancialResults #CashRunway #InvestmentNews #Biotech

Imunon GAAP EPS -$6.83 Reported Mar 31, 2026 Imunon reported GAAP EPS of -$6.83 on Mar 31, 2026 (Seeking Alpha). The result raises immediate questions about cash runway and the likelihood of dilutive financing within 6–18 months.

Imunon GAAP EPS -$6.83 Reported Mar 31, 2026: Imunon reported GAAP EPS of -$6.83 on Mar 31, 2026 (Seeking Alpha). The result raises immediate questions about cash runway and the likelihood of dilutive financing… 👈 Read full analysis #Imunon #GAAPEarnings #BiotechNews #SmallCapStocks #CashRunway

MetaVia Posts GAAP EPS of -$7.35 MetaVia reported GAAP EPS of -$7.35 on Mar 26, 2026 (Seeking Alpha); institutions must verify cash runway and covenant risk before adjusting exposure.

MetaVia Posts GAAP EPS of -$7.35: MetaVia reported GAAP EPS of -$7.35 on Mar 26, 2026 (Seeking Alpha); institutions must verify cash runway and covenant risk before adjusting exposure. 👈 Read full analysis #MetaVia #GAAP #EarningsReport #CashRunway #FinancialAnalysis